Clinical & Experimental Metastasis

, Volume 22, Issue 7, pp 565–573

MUC1, MUC2, MUC4, MUC5AC and MUC6 Expression in the Progression of Prostate Cancer

  • Paul J. Cozzi
  • Jian Wang
  • Warick Delprado
  • Alan C. Perkins
  • Barry J. Allen
  • Pamela J. Russell
  • Yong Li
Article

Abstract

Molecular changes are vital for the development of prognostic markers and therapeutic modalities of prostate cancer (CaP). There is growing interest in mucins as treatment targets in human malignancies, including CaP. The role of their expression in the progression of CaP is however unclear. We examined the expressions MUC1, MUC2, MUC4, MUC5AC and MUC6 in CaP tissues using tissue microarrays (TMAs) to look for tumor-associated antigens (TAAs) for targeted therapy. In this study, 120 paraffin-embedded specimens were selected from patients who underwent radical retro-pubic prostatectomy (RRP) or trans-urethral-resection of the prostate (TURP) for primary, untreated CaP and 10 matched lymph node metastases. A series of MUC monoclonal antibodies (mAbs) was used on TMAs by standard immunohistochemistry. Our results indicate that the over-expression of MUC1 was detected in 58% of primary CaP tissues and 90% of lymph node metastases but not in normal prostate or benign tissues, while the expression of MUC2, MUC4, MUC5AC and MUC6 was found to be negative in both normal and cancer tissues. Of the MUC1 positive tumors 86% were Gleason grade 7 or higher. Over-expression of MUC1 was found in late stage CaP while MUC2, 4, 5AC and 6 were negative in CaP. MUC1 is a TAA that is highly related to tumor progression in CaP patients. This antigen is ideal for targeted therapy to control micrometastases and hormone refractory disease but additional studies are necessary to assess its usefulness in patient biopsies and CaP bone metastases before clinical trial.

Keywords

human prostate cancer monoclonal antibodies mucins tissue microarray tumor-associated antigen 

Abbreviations

CaP

prostate cancer

mAbs

monoclonal antibodies

MRD

minimal residual disease

PIN

prostatic intra-epithelial neoplasia

PSA

prostate-specific antigen

RRP

radical retro-pubic prostatectomy

SIGLECS

sialic-acid-binding immunoglobulin superfamily lectins

SMC

sialomucin complex

TBS

tris buffered saline

TAA

tumor-associated antigens

TMA

tissue microarrays

TURP

trans-urethral-resection of the prostate

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jemal, A, Murray, T, Samuels, A,  et al. 2003Cancer statistics, 2003CA Cancer J Clin53526PubMedGoogle Scholar
  2. 2.
    Hollingsworth, MA, Swanson, BJ 2004Mucins in cancer: protection and control of the cell surfaceNat Rev44560Google Scholar
  3. 3.
    Legrier, ME, Pinieux, GD, Boye, K,  et al. 2004Mucinous differentiation features associated with hormonal escape in a human prostate cancer xenograftBr J Cancer907207CrossRefPubMedGoogle Scholar
  4. 4.
    Ho, SB, Niehans, GA, Lyftogt, Y,  et al. 1993Heterogeneity of mucin gene expression in normal and neoplastic tissuesCancer Res5364151PubMedGoogle Scholar
  5. 5.
    Live, DH, Williams, LJ, Kuduk, SD,  et al. 1999Probing cell-surface architecture through synthesis: an NMR-determined structural motif for tumor-associated mucinsPro Natl Acad Sci USA96348993Google Scholar
  6. 6.
    Moniaux, N, Escande, F, Porchet, N,  et al. 2001Structural organization and classification of the human mucin genesFrontiers Biosci6D1192206Google Scholar
  7. 7.
    Copin, MC, Buisine, MP, Leteurtre, E,  et al. 2001Mucinous bronchioloalveolar carcinomas display a specific pattern of mucin gene expression among primary lung adenocarcinomasHuman Pathol3227481Google Scholar
  8. 8.
    Pound, CR, Partin, AW, Eisenberger, MA,  et al. 1999Natural history of progression after PSA elevation following radical prostatectomyJAMA28115917CrossRefPubMedGoogle Scholar
  9. 9.
    Gleason, DF 1966Classification of prostatic carcinomasCancer Chemother Rep501258PubMedGoogle Scholar
  10. 10.
    Schroder, FH, Hermanek, P, Denis, L,  et al. 1992The TNM classification of prostate cancerProstate (Suppl)4129138Google Scholar
  11. 11.
    Kononen, J, Bubendorf, L, Kallioniemi, A,  et al. 1998Tissue microarrays for high-throughput molecular profiling of tumor specimensNat Med48447CrossRefPubMedGoogle Scholar
  12. 12.
    Li, Y, Tian, Z, Rizvi, SMA,  et al. 2002In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213-labeled J591 antibody against the prostate specific membrane antigenProstate Cancer Prostatic Dis53646PubMedGoogle Scholar
  13. 13.
    Rubin, MA, Dunn, R, Strawderman, M,  et al. 2002Tissue microarray sampling stratergy for prostate cancer biomarker analysisAm J Surg Pathol263129PubMedGoogle Scholar
  14. 14.
    Rimm, DL, Camp, RL, Charette, LA,  et al. 2001Amplification of tissue by construction of tissue microarraysExp Mol Pathol75564Google Scholar
  15. 15.
    Hakomori, S 1989Aberrant glycosylation in tumors and tumor-associated carbohydrate antigenAdv Cancer Res52257331PubMedGoogle Scholar
  16. 16.
    Gendler, S, Taylor-Papadimitriou, J, Duhig, T,  et al. 1988A high immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeatsJ Biol Chem263128203PubMedGoogle Scholar
  17. 17.
    Gaemers, IC, Vos, HL, Volders, HH,  et al. 2001ASTAT-responsive element in the promoter of the episialin/MUC1 gene is involved in its overexpression in carcinoma cellsJ Biol Chem27661919CrossRefPubMedGoogle Scholar
  18. 18.
    Bieche, I, Lidereau, R 1997A gene dosage effect is responsible for high overexpression of the MUC1 gene observed in human breast tumorsCancer Genet Cytogenet987580PubMedGoogle Scholar
  19. 19.
    Gendler, SJ, Spicer, AP 1995Epithelial mucin genesAnnu Rev Physiol5760734CrossRefPubMedGoogle Scholar
  20. 20.
    Burdick, MD, Harris, A, Reid, CJ,  et al. 1997Oligosaccharides expressed on MUC1 produced by pancreatic and colon tumor cell linesJ Biol Chem27224198202CrossRefPubMedGoogle Scholar
  21. 21.
    Taylor-Papadimitriou, J, Burchell, J, Miles, DW,  et al. 1999MUC1 and cancerBiochim Biophys Acta145530113PubMedGoogle Scholar
  22. 22.
    Hanisch, FG, Muller, S 2000MUC1: the polymorphic appearance of a human mucinGlycobiology1043949CrossRefPubMedGoogle Scholar
  23. 23.
    Wesseling, J, Valk, SW, Vos, HL,  et al. 1995Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix componentsJ Cell Biol12925565CrossRefPubMedGoogle Scholar
  24. 24.
    Konodo, K, Kohno, N, Yokoyama, A,  et al. 1998Decreased MUC1 expression induces E-cadherin-mediated cell adhesion of breast cancer cell linesCancer Res5820149Google Scholar
  25. 25.
    Feng, H, Ghazizadeh, M, Konishi, H,  et al. 2002Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomasJpn J Clin Oncol325259CrossRefPubMedGoogle Scholar
  26. 26.
    Wesseling, J, Valk, SW, Hilkens, J 1996A mechanism for inhibition of E-cadherin-mediated cell–cell adhesion by the membrane-associated mucin episialin/MUC1Mol Biol Cell756577PubMedGoogle Scholar
  27. 27.
    McDermott, KM, Crocker, PR, Harris, A,  et al. 2001Overexpression of MUC1 reconfigures the binding properties of tumor cellsInt J Cancer9478391CrossRefPubMedGoogle Scholar
  28. 28.
    Zhang, K, Baeckstrom, D, Brevinge, H,  et al. 1996Secreted MUC1 mucins lacking their cytoplasmic part and carrying sialyl-Lewis a and × epitopes from a tumor cell line and sera of colon carcinoma patients can inhibit HL-60 leukocyte adhesion to E-selectin-expressing endothelial cellsJ Cell Biochem6053849CrossRefPubMedGoogle Scholar
  29. 29.
    Brinkman-Van der Linden, EC, Varki, A 2000New aspects of siglec binding specificities, including the significance of fucosylation and of the sialyl-Tn epitope. Sialic acid-binding immunoglobulin superfamily lectins.J Biol Chem275862532PubMedGoogle Scholar
  30. 30.
    Pandey, P, Kharbanda, S, Kufe, D 1995Association of the DF3/MUC1 breast cancer antigen with Grb2 and the Sos/Ras exchange proteinCancer Res5540003PubMedGoogle Scholar
  31. 31.
    Li, Y, Bharti, A, Chen, D, Gong, J,  et al. 1998Interaction of glycogen synthase kinase 3b with the DF3/MUC1 carcinoma-associated antigen and β-cateninMol Cell Biol18721624PubMedGoogle Scholar
  32. 32.
    Hughes, ODM, Denley, H, Kunkler, RB,  et al. 2000MUC1 mucin expression in transitional cell carcinoma of the bladderJ Urol Path1217991Google Scholar
  33. 33.
    Zhang, S, Zhang, HS, Reuter, VE,  et al. 1998Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancersClin Cancer Res4295302PubMedGoogle Scholar
  34. 34.
    Kirschenbaum, A, Itzkowitz, SH, Wang, JP,  et al. 1999MUC1 expression in prostate carcinoma: correlation with grade and stageMol Urol31638PubMedGoogle Scholar
  35. 35.
    Papadopoulos, I, Sivridis, E, Giatromanolaki, A,  et al. 2001Tumor angiogenesis is associated with MUC1 overexpression and loss of prostate-specific antigen expression in prostate cancerClin Cancer Res715338PubMedGoogle Scholar
  36. 36.
    Arai, T, Fujita, K, Fujime, M,  et al. 2005Expression of sialylated MUC1 in prostate cancer: Relationship to clinical stage and prognosisInt J Urol1265361CrossRefGoogle Scholar
  37. 37.
    Schut, IC, Waterfall, PM, Ross, M,  et al. 2003MUC1 expression, splice variant and short form transcription (MUC1/Z, MUC1/Y) in prostate cell lines and tissueBJU Int9127883CrossRefPubMedGoogle Scholar
  38. 38.
    O’Connor, JC, Julian, J, Lim, SD,  et al. 2005MUC1 expression in human prostate cancer cell lines and primary tumorsProstate Cancer Prostatic Dis83644PubMedGoogle Scholar
  39. 39.
    Lapointe, L, Li, CD, Higgins, JP,  et al. 2004Gene expression profiling identifies clinically relevant subtypes of prostate cancerProc Natl Acad Sci USA1018116CrossRefPubMedGoogle Scholar
  40. 40.
    McGucki, MA, Walsh, MD, Hohn, BG,  et al. 1995Prognostic significance of MUC1 epithelial mucin expression in breast cancerHum Pathol264329Google Scholar
  41. 41.
    Sagara, M, Yonezawa, S, Nagata, K,  et al. 1999Expression of mucin 1 (MUC1) in esophageal squamous-cell carcinoma: its relationship with prognosisInt J Cancer842517CrossRefPubMedGoogle Scholar
  42. 42.
    Fujita, K, Denda, K, Yamamoto, M,  et al. 1999Expression of MUC1 mucin inversely correlated with post-surgical survival of renal cell carcinoma patientsBr J Cancer803018CrossRefPubMedGoogle Scholar
  43. 43.
    Satoh, S, Hinoda, Y, Hayashi, T,  et al. 2000Enhancement of metastatic properties of pancreatic cancer cells by MUC1 gene encoding an anti-adhesion moleculeInt J Cancer8850718CrossRefPubMedGoogle Scholar
  44. 44.
    Li, Y, Rizvi, SMA, Brown, JM,  et al. 2004Antigenic expression human metastatic prostate cancer cell lines for in vitro multiple targeted alpha therapy 213Bi-conjugatedInt J Radiat Oncol Biol Phys60896908CrossRefPubMedGoogle Scholar
  45. 45.
    Qu, CF, Li, Y, Song, YJ,  et al. 2004MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by 213Bi-C595 radioimmunoconjugateBr J Cancer91208693CrossRefPubMedGoogle Scholar
  46. 46.
    Doehn, C, Jocham, D 2000Technology evaluation: TG-1031, transgene SACurr Opin Mol Ther210611PubMedGoogle Scholar
  47. 47.
    Morse, MA 2001Technology evaluation: BLP-25, Biomira, IncCurr Opin Mol Ther31025PubMedGoogle Scholar
  48. 48.
    Pantuck, AJ, Ophoven, A, Gitlitz, BJ,  et al. 2004Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancerJ Immunother2724053PubMedGoogle Scholar
  49. 49.
    Hollingsworth, MA, Strawhecker, JM, Caffrey, TC,  et al. 1994Expression of MUC1, MUC2, MUC3 and MUC4 mucin mRNAs in human pancreatic and intestinal tumour cell lineInt J Cancer57198203PubMedGoogle Scholar
  50. 50.
    Swartz, MJ, Batra, SK, Varshney, GC,  et al. 2002MUC4 expression increases progressively in pancreatic intraepithelial neoplasiaAm J Clin Pathol1177916CrossRefPubMedGoogle Scholar
  51. 51.
    Komatsu, M, Tatum, L, Altman, NH,  et al. 2000Potentiation of metastasis by cell surface sialomucin complex (rat MUC4), a multifunctional anti-adhesive glycoproteinInt J Cancer874806CrossRefPubMedGoogle Scholar
  52. 52.
    Seuningen, I, Pigny, P, Perrais, M,  et al. 2001Transcriptional regulation of the 11p15 mucin genes: towards new biological tools in human therapy, in inflammatory disease and cancer?Front Biosci6D121634PubMedGoogle Scholar
  53. 53.
    Leroy, X, Ballereau, C, Villers, A,  et al. 2003MUC6 is a marker of seminal vesicle-ejaculatory duct epithelium and is useful for the differential diagnosis with prostate adenocarcinomaAm J Surg Pathol2751921CrossRefPubMedGoogle Scholar

Copyright information

© Springer 2006

Authors and Affiliations

  • Paul J. Cozzi
    • 1
    • 2
  • Jian Wang
    • 2
    • 3
  • Warick Delprado
    • 4
  • Alan C. Perkins
    • 5
  • Barry J. Allen
    • 2
    • 3
  • Pamela J. Russell
    • 2
    • 6
  • Yong Li
    • 2
    • 3
  1. 1.Department of SurgerySt George HospitalKogarahAustralia
  2. 2.Department of MedicineUniversity of New South WalesKensingtonAustralia
  3. 3.Center for Experimental Radiation Oncology, Cancer Care CenterSt George HospitalKogarahAustralia
  4. 4.Douglass Hanly Moir PathologyNorth RydeAustralia
  5. 5.Department of Medical Physics, Medical SchoolQueen’s Medical CentreNottinghamUnited Kingdom
  6. 6.Oncology Research CenterPrince of Wales HospitalRandwickAustralia

Personalised recommendations